The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
HOME > ARCHIVE
ARCHIVE
- Over 90% of Nursing Staff Have Committed or Nearly Committed Errors
March 12, 2001
- Japan Tobacco to Make Pharma Business Profitable in FY2005
March 12, 2001
- BUSINESS NEWS IN BRIEF -2-
March 12, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 12, 2001
- Dainippon to Report Record-high Sales, Profits Again: President Miyatake
March 12, 2001
- Strategic Value of Product Forecasting Is Critical: Dr Ramsey of Mattson Jack Group
March 12, 2001
- Chugai Forms Functional Genomics Alliance with Immusol
March 12, 2001
- Domestic Market for CRO Business Estimated to Be \150 Bil.: CMIC President
March 12, 2001
- Next-generation Vitamin D Expected to Be Effective for Colon Cancer: Chugai Seminar
March 12, 2001
- IFPMA Creates Task Force on Access to Anti-AIDS Drugs
March 12, 2001
- AstraZeneca to Launch 3 New Drugs per Year in All Major Markets
March 5, 2001
- Large Intervention Study on Hypertension Targets 9,000 Patients in Japan
March 5, 2001
- DIAGNOSTIC NEWS IN BRIEF
March 5, 2001
- Korosho to Deal with Biologics in Earnest
March 5, 2001
- Korosho to Issue GL Regarding NAT for HBV, HCV, HIV
March 5, 2001
- JPMA Invites Participation in Protein Structure Analysis Consortium
March 5, 2001
- 39 New Drugs Approved in 2000: PMSB
March 5, 2001
- Individual Health Insurance Cards to Be Introduced in April
March 5, 2001
- JPMA Calls For Maintenance of NHI Price Listing by Brand Name
March 5, 2001
- GL for Investigational Use of ES Cells Proposed
March 5, 2001
ページ
Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…